Skip to main content

Table 1 Patient and treatment characteristics

From: Feasibility of 7-T fluorine magnetic resonance spectroscopic imaging (19F MRSI) for TAS-102 metabolite detection in the liver of patients with metastatic colorectal cancer

 

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Age (years)

66

60

31

63

63

Sex

Female

Male

Female

Male

Male

BMI (kg/m2)

20.9

24.2

29.3

19.4

25.4

History of oncologic treatment of the liver

Hemihepatectomy

Radio-embolisation

Partial hepatectomy

None

None

TAS-102 dosage

50 mg b.i.d.

65 mg b.i.d.

55 mg b.i.d.

60 mg b.i.d.

70 mg b.i.d.

Cycle number

Cycle 2 day 8

Cycle 1 day 9

Cycle 1 day 9

Cycle 1 day 9

Cycle 1 day 9

Time of response evaluation according to RECIST

After 4 cycles TAS-102

After 3 cycles TAS-102

After 3 cycles TAS-102

After 3 cycles TAS-102

After 3 cycles TAS-102

Time to first disease progression (progression-free survival)

3.7 months

2.8 months

2.8 months

2.8 months

2.8 months

Time between oral intake of TAS-102 and first MRS examination

30 min

90 min

105 min

150 min

60 min

Timing of both localised CSI scans

14.24 min

14.24 min

14.24 min

14.24 min

14.24 min

  1. Abbreviations: BMI body mass index, b.i.d. bi-daily, CSI chemical shift imaging, min minutes, MRS magnetic resonance spectroscopy, RECIST Response Evaluation Criteria In Solid Tumours, TAS-102 trifluridine/tipiracil